title: Nanoformulation of natural products for prevention and therapy of prostate cancer.
abstract: There is a need for developing improved therapeutic options for the management of prostate cancer, able to inhibit proliferation of precancerous and malignant lesions and/or to improve the effectiveness of conventional chemopreventive and chemotherapeutic agents. In this perspective, application of nanotechnology based strategies for the delivery of natural compounds for effective management of the disease is being actively researched. Here, after highlighting the most promising natural compounds for chemoprevention and chemotherapy of prostate cancer, the state of the art nanotherapeutics and the recent proof-of-concept of "nanochemoprevention", as well as the clinical development of promising targeted nanoprototypes for use in the prostate cancer treatment are being discussed.
authors.affiliation: Department of Dermatology, University of Wisconsin, Madison, WI, USA; Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Italy.
authors.forename: Vanna
authors.initials: V
authors.lastname: Sanna
authors.affiliation: Department of Dermatology, University of Wisconsin, Madison, WI, USA.
authors.forename: Imtiaz A
authors.initials: IA
authors.lastname: Siddiqui
authors.affiliation: Department of Dermatology, University of Wisconsin, Madison, WI, USA; Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Sechi
authors.affiliation: Department of Dermatology, University of Wisconsin, Madison, WI, USA. Electronic address: hmukhtar@wisc.edu.
authors.forename: Hasan
authors.initials: H
authors.lastname: Mukhtar
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D000954:Antigens, Surface / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D000077143:Docetaxel; D043425:Glutamate Carboxypeptidase II / Q000378:metabolism; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D053758:Nanoparticles / Q000008:administration & dosage; D036103:Nanotechnology / Q000379:methods*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D043823:Taxoids / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D016588:Anticarcinogenic Agents; D000954:Antigens, Surface; D000970:Antineoplastic Agents; D001688:Biological Products; D043823:Taxoids; D000077143:Docetaxel; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II